← Back to Search
Glucagon-like peptide-1 receptor agonist
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy (RAISE-KT Trial)
Wilkes-Barre, PA
Phase 3
Waitlist Available
Led By Alex R Chang, MD, MS
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 9 months
Awards & highlights
Pivotal Trial
Summary
This trial looks at whether semaglutide, a diabetes medication, can help people with diabetes and kidney disease who are overweight or obese.
See full description
Eligible Conditions
- Diabetic Kidney Disease
- Diabetes
- Obesity
- Chronic kidney disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Kidney Transplant Eligibility
Secondary study objectives
Change in BMI
Change in Body Fat Percentage
Change in Hemoglobin A1c (HgbA1c)
+4 moreOther study objectives
All-cause Hospitalizations
Cardiovascular Disease (CVD) Events
Change in Albuminuria Among Subset of Participants Without End-stage Kidney Disease
+15 moreAwards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: SemaglutideActive Control1 Intervention
This arm will receive semaglutide.
Group II: PlaceboPlacebo Group1 Intervention
This arm will receive placebo.
Find a Location
Closest Location:Geisinger Wyoming Valley· Wilkes-Barre, PA
Who is running the clinical trial?
Geisinger ClinicLead Sponsor
158 Previous Clinical Trials
1,976,279 Total Patients Enrolled
Alex R Chang, MD, MSPrincipal InvestigatorGeisinger Clinic
1 Previous Clinical Trials
31 Total Patients Enrolled